IDiyas

For the Inventor, By the Inventor

Birkerød, Denmark

Majken Westergaard

USPTO Granted Patents = 17 

 

Average Co-Inventor Count = 5.7

ph-index = 9

Forward Citations = 735(Granted Patents)


Location History:

  • Birkerød, DK (2010)
  • Birkerod, DK (2009 - 2018)

Company Filing History:

goldMedal10 out of 44 
 
Santaris Pharma A/s
 patents
silverMedal7 out of 52 
 
Enzon Pharmaceuticals, Inc.
 patents
bronzeMedal7 out of 46 
 
Roche Innovation Center Copenhagen A/s
 patents
where one patent can have more than one assignee

Years Active: 2009-2018

Loading Chart...
Loading Chart...
17 patents (USPTO):
1. 9994850 - Antisense design (2018-06-12),
2. 9951333 - Antisense design (2018-04-24),
3. 9938527 - Potent LNA oligonucleotides for the inhibition of HIF-1A expression (2018-04-10),
4. 9890383 - Antisense design (2018-02-13),
5. 9708614 - Antisense design (2017-07-18),
6. 9447138 - Potent LNA oligonucleotides for the inhibition of HIF-1a expression (2016-09-20),
7. 9428534 - Antisense design (2016-08-30),
8. 9045518 - Amino-LNA, thio-LNA and alpha-L-oxy-LN (2015-06-02),
9. 8410071 - Potent LNA oligonucleotides for the inhibition of HIF-1A expression (2013-04-02),
10. 8173428 - LNA oligonucleotides and the treatment of cancer (2012-05-08),
11. 8026355 - Oligomeric compounds for the modulation of survivin expression (2011-09-27),
12. 7939507 - Potent LNA oligonucleotides for the inhibition of HIF-1a expression (2011-05-10),
13. 7741309 - Oligomeric compounds for the modulation of survivin expression (2010-06-22),
14. 7713738 - Oligomeric compounds for the modulation of survivin expression (2010-05-11),
15. 7687617 - Oligonucleotides with alternating segments of locked and non-locked nucleotides (2010-03-30),

Certainly! Here is an article about inventor Majken Westergaard:

Title: Majken Westergaard: Pioneering Innovations in Antisense Therapy

Introduction:

Majken Westergaard, a prolific inventor in the field of pharmaceuticals, hails from Birkerod, Denmark. With an impressive 17 patents to his name, he is a leading figure in the development of novel oligonucleotides for antisense therapy.

Latest Patents:

Westergaard's latest patents revolve around the groundbreaking "Antisense design" - a unique class of pharmaceuticals that incorporate Locked Nucleic Acid (LNA) for enhanced antisense properties. These oligonucleotides, composed of specialized LNAs, show exceptional promise in the realm of antisense therapy for various medical applications.

Career Highlights:

Throughout his career, Majken Westergaard has made significant contributions to companies like Santaris Pharma A/S and Enzon Pharmaceuticals, Inc. His innovative work has paved the way for advancements in drug development and therapeutic solutions.

Collaborations:

Collaborating closely with esteemed colleagues such as Charlotte Albaek Thrue and Henrik Frydenlund Hansen, Westergaard has fostered a culture of innovation and excellence. Together, they have propelled cutting-edge research in the field of pharmaceuticals.

Conclusion:

In conclusion, Majken Westergaard's dedication to pushing the boundaries of pharmaceutical innovation is truly commendable. His inventive approach and collaborative spirit continue to shape the landscape of antisense therapy, offering new hope for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…